iTAG's new approach to imaging leads to:

Compatibility with most genetic vector types including lentiviral, AAV, and mRNA.

Vertical Divider

Non-invasive imaging, requiring no biopsy.

Vertical Divider

The ability to assess the pharmacokinetics and spatiotemporal dynamics of therapies.

Learn How

iTAG allows for measuring and monitoring the biodistribution, expansion, contraction, and persistence of CAR T cells in various tissues and organs.

Vertical Divider

The reporter gene being passed on to daughter cells allowing for repeat imaging.

Learn How

Direct labeling with radioactivity leads to single measurements and uptake often occuring in multiple ​varieties of cells.

Indirect labeling with iTAG allows repeat measurements and uptake only in therapeutic cells.

Our vision is that iTAG will provide value across the entire drug discovery process, development, and clinical use spectrum

TMP tracer is well suited for clinical use

TMP PET tracer clearance profile in humans appears amenable to accommodate many cancer CAR T indications

Vertical Divider

Paired radiotracer:
​[F-18]FP-TMP

Reporter protein:
eDHFR​

Vertical Divider

iTAG has ideal characteristics and is differentiated from other PET reporter genes